Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Milton C. Ault IIIDirector | Alzamend NeuroALZN | Open-market buy | 04/14 | 04/16 | 108,388 sh | $1.00 | $108,388 | +1312.2% |
Milton C. Ault IIIDirector | Alzamend NeuroALZN | Open-market sale | 25/12/23 | 25/12/30 | 1,851 sh | $2.07 | $3,831.57 | −100.0% |
William B. HorneDirector | Alzamend NeuroALZN | Open-market sale | 25/12/19 | 25/12/23 | 3,333 sh | $2.12 | $7,065.96 | −100.0% |
Lynne Fahey McGrathDirector | Alzamend NeuroALZN | Open-market sale | 25/10/23 | 25/10/24 | 30 sh | $2.29 | $68.7 | −54.5% |
Alzamend NeuroALZN | Open-market sale | 25/10/08–25/10/09 | 25/10/10 | 121,791 sh2 trades | $2.42avg. | $294,722.4 | −93.6% | |
Alzamend NeuroALZN | Open-market sale | 25/10/06–25/10/07 | 25/10/08 | 139,412 sh2 trades | $2.47avg. | $343,854.56 | −66.9% | |
Alzamend NeuroALZN | Open-market sale | 25/10/01–25/10/03 | 25/10/03 | 123,366 sh3 trades | $2.40avg. | $296,668.81 | −93.7% | |
Alzamend NeuroALZN | Open-market sale | 25/09/26–25/09/30 | 25/09/30 | 79,628 sh3 trades | $2.31avg. | $184,012 | −71.6% | |
Alzamend NeuroALZN | Open-market sale | 25/09/23–25/09/25 | 25/09/25 | 97,006 sh3 trades | $2.34avg. | $227,110.52 | −89.6% | |
Milton C. Ault IIIDirector | Alzamend NeuroALZN | Open-market sale | 25/09/19 | 25/09/23 | 77,009 sh | $2.35 | $180,971.15 | −90.3% |
Alzamend NeuroALZN | Open-market sale | 25/09/17–25/09/18 | 25/09/19 | 22,991 sh2 trades | $2.47avg. | $56,745.35 | −21.2% | |
Alzamend NeuroALZN | Open-market sale | 25/07/30–25/07/31 | 25/08/01 | 129,449 sh2 trades | $2.29avg. | $295,916.99 | −94.0% | |
Alzamend NeuroALZN | Open-market sale | 25/07/25–25/07/28 | 25/07/29 | 44,843 sh2 trades | $2.86avg. | $128,216.28 | −54.3% | |
Alzamend NeuroALZN | Open-market sale | 25/07/23–25/07/24 | 25/07/25 | 69,137 sh2 trades | $2.95avg. | $203,761.73 | −45.6% | |
Alzamend NeuroALZN | Open-market sale | 25/05/12 | 25/05/14 | 1,224 sh2 trades | $5.06avg. | $6,195.86 | No record | |
William B. HorneDirector | Alzamend NeuroALZN | Open-market buy | 25/03/26 | 25/03/27 | 3,334 sh | $0.99 | $3,300.66 | +12.5% |
Milton C. Ault IIIDirector | Alzamend NeuroALZN | Open-market buy | 25/03/21 | 25/03/25 | 2,905 sh | $1.02 | $2,963.1 | +3.5% |
Alzamend NeuroALZN | Open-market buy | 25/03/21 | 25/03/24 | 5,000 sh | $1.01 | $5,050 | +925.9% | |
William B. HorneDirector | Alzamend NeuroALZN | Open-market buy | 25/03/20 | 25/03/20 | 5,000 sh | $0.98 | $4,900 | +23.1% |
William B. HorneDirector | Alzamend NeuroALZN | Open-market buy | 25/03/18 | 25/03/19 | 5,000 sh | $0.97 | $4,850 | +30.0% |